Daily US Times: The Covid-19 patients who are getting an experimental drug called remdesivir have been recovering quickly, with most going home in days. STAT News reported it on Thursday after it obtained a video of a conversation about the trial.
A doctor leading the trial said STAT that patients who are taking part in a clinical trial of the drug have all had severe fever and respiratory symptoms, but were able to leave the hospital after less than a week of treatment.
Dr. Kathleen Mullane is leading the clinical trial, who is an infectious disease specialist at the University of Chicago. She said in the video: “The best news is that most of our patients have already been discharged, which is great. We’ve only had two patients perish.”
The University of Chicago issued a statement about the matter which claims Mullane’s comments constituted partial information.
The statement says: “Partial data from an ongoing clinical trial is by definition incomplete and should never be used to draw conclusions about the safety or efficacy of a potential treatment that is under investigation.”
“In this case, information from an internal forum for research colleagues concerning work in progress was released without authorization. Drawing any conclusions at this point is premature and scientifically unsound.”
Gilead Sciences made the drug and it was previously tested against Ebola with little success. Multiple studies in animals showed the drug could both prevent and treat coronaviruses related to Covid-19, including MERS (Middle East Respiratory Syndrome) and SARS (Severe Acute Respiratory Syndrome).
The World Health Organization said remdesivir showed potential against Covid-19 back in February.
STAT said it obtained and viewed a copy of the video discussion Mullane had last week with colleagues about the trial.
She said most of their patients are severe and most of them are leaving at six days, so that tells the duration of therapy doesn’t have to be 10 days.
Dozens of drugs are ongoing in other clinical centers.
Gilead is sponsoring tests of the drug in 152 trial sites around the world with 2,400 patients who have severe Covid-19 symptoms.
It’s also testing the drug in 1,600 patients with moderate symptoms at 169 clinics and hospitals across the world.
The company said it expected results from the trial by the end of the month.
Gilead said in a statement to CNN: “The totality of the data need to be analyzed in order to draw any conclusions from the trial. Anecdotal reports, while encouraging, do not provide the statistical power necessary to determine the safety and efficacy profile of remdesivir as a treatment for Covid-19.”